Phase 1/1b Trial of Donor gamma delta T-cell Infusion for Treatment of Patients with Acute Myeloid Leukemia at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with Acute Myeloid Leukemia (AML).
Primary: 1) The primary objective of this study dose finding phase is to determine the maximal tolerated dose (MTD) of AAPC-expanded donor γδ T-cells administered after alloHCT as a single infusion to AML patients with MRD detectable disease.
2) The primary objective of the extension phase is to assess the potential efficacy of AAPC expanded donor γδ T-cells in AML patients with MRD detectable disease.
Secondary: 1) Assess the quality of donor γδ T-cell production.
2) Determine the incidence of grade II-IV and III-IV acute GVHD within 6 weeks after infusion of γδ T cells.
3) Assess the effect of AAPC expanded donor γδ T-cells on hematological relapse and OS at 1-year after infusion of γδ T-cells.
Male or female, aged between 18 and 75 years of age undergoing allogeneic hematopoietic stem cell transplantation (alloHCT) or the treatment of Acute Myeloid Leukemia (AML) with detectable minimal residual disease (MRD) either before or after alloHCT
Have > Karnofsky performance status (KPS) ≥ 70% during the study screening.
Free of symptomatic congestive heart failure or uncontrolled arrhythmia
Adequate organ function as defined in protocol
Negative serum pregnancy test
Note: Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for at least 30 days following study treatment (T-cell infusion); should a woman subject or female partner of a male subject become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study.
Agreement to adhere to Lifestyle Considerations throughout study duration
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub